TRAVERE THERAPEUTICS INC (TVTX) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:TVTX • US89422G1076

30.32 USD
+0.25 (+0.83%)
At close: Feb 10, 2026
30.32 USD
0 (0%)
After Hours: 2/10/2026, 5:20:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, TVTX scores 3 out of 10 in our fundamental rating. TVTX was compared to 523 industry peers in the Biotechnology industry. Both the profitability and financial health of TVTX have multiple concerns. TVTX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year TVTX has reported negative net income.
  • In the past year TVTX has reported a negative cash flow from operations.
  • In the past 5 years TVTX always reported negative net income.
  • TVTX had a negative operating cash flow in each of the past 5 years.
TVTX Yearly Net Income VS EBIT VS OCF VS FCFTVTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -16.44%, TVTX is in the better half of the industry, outperforming 78.39% of the companies in the same industry.
  • TVTX has a Return On Equity of -120.36%. This is comparable to the rest of the industry: TVTX outperforms 41.11% of its industry peers.
Industry RankSector Rank
ROA -16.44%
ROE -120.36%
ROIC N/A
ROA(3y)-36.55%
ROA(5y)-32.15%
ROE(3y)-416.31%
ROE(5y)-277.75%
ROIC(3y)N/A
ROIC(5y)N/A
TVTX Yearly ROA, ROE, ROICTVTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

  • TVTX has a better Gross Margin (97.63%) than 97.32% of its industry peers.
  • In the last couple of years the Gross Margin of TVTX has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for TVTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.63%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.11%
GM growth 5Y-0.07%
TVTX Yearly Profit, Operating, Gross MarginsTVTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • TVTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • TVTX has more shares outstanding than it did 1 year ago.
  • TVTX has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for TVTX is higher compared to a year ago.
TVTX Yearly Shares OutstandingTVTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
TVTX Yearly Total Debt VS Total AssetsTVTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of 0.42, we must say that TVTX is in the distress zone and has some risk of bankruptcy.
  • TVTX has a Altman-Z score of 0.42. This is in the better half of the industry: TVTX outperforms 62.14% of its industry peers.
  • A Debt/Equity ratio of 4.23 is on the high side and indicates that TVTX has dependencies on debt financing.
  • TVTX's Debt to Equity ratio of 4.23 is on the low side compared to the rest of the industry. TVTX is outperformed by 80.31% of its industry peers.
Industry RankSector Rank
Debt/Equity 4.23
Debt/FCF N/A
Altman-Z 0.42
ROIC/WACCN/A
WACC11.93%
TVTX Yearly LT Debt VS Equity VS FCFTVTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M

2.3 Liquidity

  • A Current Ratio of 2.75 indicates that TVTX has no problem at all paying its short term obligations.
  • The Current ratio of TVTX (2.75) is worse than 67.11% of its industry peers.
  • A Quick Ratio of 2.71 indicates that TVTX has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 2.71, TVTX is doing worse than 66.16% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.75
Quick Ratio 2.71
TVTX Yearly Current Assets VS Current LiabilitesTVTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 75.91% over the past year.
  • The Revenue has grown by 114.22% in the past year. This is a very strong growth!
  • The Revenue has been growing slightly by 5.87% on average over the past years.
EPS 1Y (TTM)75.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%140%
Revenue 1Y (TTM)114.22%
Revenue growth 3Y0.82%
Revenue growth 5Y5.87%
Sales Q2Q%162.11%

3.2 Future

  • The Earnings Per Share is expected to grow by 29.30% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, TVTX will show a very strong growth in Revenue. The Revenue will grow by 41.46% on average per year.
EPS Next Y91.26%
EPS Next 2Y47.13%
EPS Next 3Y34.58%
EPS Next 5Y29.3%
Revenue Next Year118.08%
Revenue Next 2Y72.72%
Revenue Next 3Y55.73%
Revenue Next 5Y41.46%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TVTX Yearly Revenue VS EstimatesTVTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
TVTX Yearly EPS VS EstimatesTVTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 10

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • TVTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • The Price/Forward Earnings ratio is 44.89, which means the current valuation is very expensive for TVTX.
  • Based on the Price/Forward Earnings ratio, TVTX is valued cheaper than 90.82% of the companies in the same industry.
  • TVTX is valuated expensively when we compare the Price/Forward Earnings ratio to 27.97, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 44.89
TVTX Price Earnings VS Forward Price EarningsTVTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TVTX Per share dataTVTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • TVTX's earnings are expected to grow with 34.58% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y47.13%
EPS Next 3Y34.58%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • TVTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TRAVERE THERAPEUTICS INC

NASDAQ:TVTX (2/10/2026, 5:20:02 PM)

After market: 30.32 0 (0%)

30.32

+0.25 (+0.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30
Earnings (Next)02-19
Inst Owners112.9%
Inst Owner Change-2.99%
Ins Owners0.79%
Ins Owner Change4.47%
Market Cap2.71B
Revenue(TTM)435.83M
Net Income(TTM)-88.54M
Analysts84.76
Price Target42.91 (41.52%)
Short Float %18.56%
Short Ratio6.87
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)143%
Min EPS beat(2)53.91%
Max EPS beat(2)232.09%
EPS beat(4)3
Avg EPS beat(4)68.35%
Min EPS beat(4)-27.29%
Max EPS beat(4)232.09%
EPS beat(8)4
Avg EPS beat(8)26.91%
EPS beat(12)6
Avg EPS beat(12)-40.48%
EPS beat(16)6
Avg EPS beat(16)-36.6%
Revenue beat(2)2
Avg Revenue beat(2)31.6%
Min Revenue beat(2)11.48%
Max Revenue beat(2)51.72%
Revenue beat(4)3
Avg Revenue beat(4)17.32%
Min Revenue beat(4)-0.02%
Max Revenue beat(4)51.72%
Revenue beat(8)6
Avg Revenue beat(8)9.84%
Revenue beat(12)9
Avg Revenue beat(12)2.67%
Revenue beat(16)9
Avg Revenue beat(16)-7.53%
PT rev (1m)1.38%
PT rev (3m)17.87%
EPS NQ rev (1m)65.34%
EPS NQ rev (3m)68.78%
EPS NY rev (1m)27.78%
EPS NY rev (3m)61.59%
Revenue NQ rev (1m)1.99%
Revenue NQ rev (3m)2.13%
Revenue NY rev (1m)0.56%
Revenue NY rev (3m)6.02%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 44.89
P/S 6.22
P/FCF N/A
P/OCF N/A
P/B 36.88
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.06
EYN/A
EPS(NY)0.68
Fwd EY2.23%
FCF(TTM)-1.2
FCFYN/A
OCF(TTM)-0.66
OCFYN/A
SpS4.87
BVpS0.82
TBVpS-0.4
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -16.44%
ROE -120.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.63%
FCFM N/A
ROA(3y)-36.55%
ROA(5y)-32.15%
ROE(3y)-416.31%
ROE(5y)-277.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.11%
GM growth 5Y-0.07%
F-Score6
Asset Turnover0.81
Health
Industry RankSector Rank
Debt/Equity 4.23
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 89.32%
Cap/Sales 11.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.75
Quick Ratio 2.71
Altman-Z 0.42
F-Score6
WACC11.93%
ROIC/WACCN/A
Cap/Depr(3y)142.8%
Cap/Depr(5y)123.81%
Cap/Sales(3y)28.66%
Cap/Sales(5y)21.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)75.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%140%
EPS Next Y91.26%
EPS Next 2Y47.13%
EPS Next 3Y34.58%
EPS Next 5Y29.3%
Revenue 1Y (TTM)114.22%
Revenue growth 3Y0.82%
Revenue growth 5Y5.87%
Sales Q2Q%162.11%
Revenue Next Year118.08%
Revenue Next 2Y72.72%
Revenue Next 3Y55.73%
Revenue Next 5Y41.46%
EBIT growth 1Y67.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year106.01%
EBIT Next 3Y45.04%
EBIT Next 5Y34.35%
FCF growth 1Y64.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.81%
OCF growth 3YN/A
OCF growth 5YN/A

TRAVERE THERAPEUTICS INC / TVTX FAQ

What is the ChartMill fundamental rating of TRAVERE THERAPEUTICS INC (TVTX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to TVTX.


What is the valuation status for TVTX stock?

ChartMill assigns a valuation rating of 3 / 10 to TRAVERE THERAPEUTICS INC (TVTX). This can be considered as Overvalued.


How profitable is TRAVERE THERAPEUTICS INC (TVTX) stock?

TRAVERE THERAPEUTICS INC (TVTX) has a profitability rating of 2 / 10.